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Abstract
Background: As the resource implications of expanding anti-retroviral therapy (ART) are likely
to be large, there is a need to explore its cost-effectiveness. So far, there is no such information
available from Ethiopia.
Objective: To assess the cost-effectiveness of ART for routine clinical practice in a district
hospital setting in Ethiopia.
Methods: We estimated the unit cost of HIV-related care from the 2004/5 fiscal year expenditure
of Arba Minch Hospital in southern Ethiopia. We estimated outpatient and inpatient service use
from HIV-infected patients who received care and treatment at the hospital between January 2003
and March 2006. We measured the health effect as life years gained (LYG) for patients receiving
ART compared with those not receiving such treatment. The study adopted a health care provider
perspective and included both direct and overhead costs. We used Markov model to estimate the
lifetime costs, health benefits and cost-effectiveness of ART.
Findings: ART yielded an undiscounted 9.4 years expected survival, and resulted in 7.1 extra LYG
compared to patients not receiving ART. The lifetime incremental cost is US$2,215 and the
undiscounted incremental cost per LYG is US$314. When discounted at 3%, the additional LYG
decreases to 5.5 years and the incremental cost per LYG increases to US$325.
Conclusion: The undiscounted and discounted incremental costs per LYG from introducing ART
were less than the per capita GDP threshold at the base year. Thus, ART could be regarded as
cost-effective in a district hospital setting in Ethiopia.
Background
In 2003, some selected health institutions started to offer
anti-retroviral therapy (ART) in Ethiopia. In 2005, a
nationwide ART programme was launched and the service
was decentralised to health centres in 2006 [1]. By March
2009, the number of treatment sites had reached 343, and
189,267 patients (56% of those in need) received ART [2].
According to the official Ministry of Health (MOH)
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2009 was estimated at 2.3 %, with about 336,160 adults
and 20,522 children being in need of ART [3].
Given the growing need for ART in Ethiopia, the resource
implications of expanding the treatment is likely to be
great. Therefore, it is necessary to consider whether pro-
viding ART is worth doing compared with treating and
caring for HIV patients without ART, and if so, how much
extra resources would be needed to treat an HIV patient
with ART in Ethiopia. These questions have direct rele-
vance to the further expansion of ART, and the answers
may facilitate resource mobilization in the country. Thus,
there is a need to know the cost and effectiveness of ART
in routine clinical practice.
The evidence on the cost-effectiveness of ART from Africa,
though still meagre, suggest that ART is a cost effective
intervention in developing countries [4-6]. Two studies
from South Africa [4,7] suggest that ART is cost-effective
compared to no-ART. One of these [4] found, based on
2004 prices, an average per person year (PPY) cost of ART
ranging from US$850 to US$1,645 with an incremental
cost that range from being cost saving to US$1,772 per life
year gained (LYG). The other study [7] reported, based on
2003 prices, an undiscounted and discounted incremen-
tal costs of US$1,023 and US$984 respectively per LYG. A
study from Cote d'Ivoire, a low income country and there-
fore more comparable with Ethiopia [8], reported a dis-
counted incremental cost of ART ranging from US$542 to
US$829 per LYG based on 2002 prices [9]. A region-based
study on ART by Hogan et al. [5] reported an incremental
cost, in the year 2000's international dollars, ranging from
$556 to $596 per disability-adjusted life years (DALYs) for
sub-Saharan countries.
As illustrated above, the health economic evidence of ART
in resource-constrained countries is limited. Much of
what is available has also come from South Africa, which
is an upper middle income country [8] and wealthier than
typical sub-Saharan countries. The region-based studies
also represent larger African regions and may not neces-
sarily represent the conditions in individual countries.
Specifically, there is no information from Ethiopia. Our
study aims to assess the cost-effectiveness of ART in a rou-
tine clinical practice setting in southern Ethiopia.
Methods
Study setting
We carried out our study at an HIV clinic at Arba Minch
Hospital (AMH) in the Southern Nation, Nationalities
and Peoples' Region (SNNPR) in Ethiopia. The hospital
started offering ART in August 2003, and follows national
and World Health Organaization (WHO) recommenda-
tions [10-12] in the management of the program. The ART
regimens for adults included the following combinations
of first-line drugs: (Stavudine-Lamivudine-Nevirapine),
(Zidovudine-Lamivudine-Nevirapine), (Stavudine-Lami-
vudine-Efavirenz) and (Zidovudine-Lamivudine-Efa-
virenz). The HIV clinic at AMH had one physician, one
nurse, one data clerk and two community healthworkers.
Those patients who were not on ART come to the clinic
every three month for followup whereas those on ART
come every month for monitoring and medication refill.
Upon visit to the clinic, all HIV patients see a doctor. Fur-
ther account of the setting is presented elswhere [13].
Study design
Our study compares the costs and health outcomes of ART
with the alternative scenario of treating and caring for HIV
patients without ART (no-ART) for routine clinical prac-
tice at a district hospital. The comparator no-ART involves
treatment of opportunistic infections and prophylaxis
with cotrimoxazole, but no anti-retroviral drugs. The
measure of health effect is LYG under no-ART and ART.
The study adopts a health care provider perspective and
focuses on hospital costs. We used a Markov life cycle
model to analyse the lifetime cost and effects of the two
treatment alternatives.
Model characteristics
Markov modelling is suitable for analysing different out-
comes when the clinical course of the disease has an
extended time horizon, and when the nature of the condi-
tion is such that patients experience different health states
at different points in time. The technique allows estimat-
ing life expectancies and lifetime costs [14-16]. We based
our model on the WHO HIV clinical staging system [12],
grouping the four clinical stages into two health states:
non-AIDS HIV state (i.e. WHO clinical stages I, II & III);
and AIDS state (i.e. WHO stage IV). The two alive clinical
states of the HIV disease (i.e. no-AIDS and AIDS states)
and the 'dead' state (i.e. death from AIDS) form the three
states in the Markov model of our study (Figure 1).
We set the length of the Markov cycle to three months;
and populated the model with transition probabilities
and average cycle costs. The transition probabilities are
the risks of progressing to the next worst health state
within a 3-month period, whereas the cycle cost is the
average cost of service use associated with staying in each
of the Markov states in a 3-month period. Then patients in
each of the comparators and respective AIDS states were
evaluated at the end of each cycle (3 month) to determine
whether they remained in their current state or had moved
to the next worse state. We repeated this, through cohort
simulation, for several cycles over an extended period of
time to estimate life expectancy and life time cost. We
used beta distribution for the transition probabilities and
gamma distribution for the costs during the analysis.Page 2 of 11
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transition probabilities and the average costs) from an
observational data of patients who received care and treat-
ment at Arba Minch hospital HIV clinic. The detail is given
below.
Study subjects
We collected outpatient service use and corresponding
cost and effect data from two prospective cohorts of HIV
patients who received care and treatment at Arba Minch
Hospital from January 2003 to March 2006 [17-19]. The
first cohort comprised HIV patients who received care
without ART at the HIV clinic from January 2003 to April
2004 (15 months). The second cohort was made up of
HIV patients who received ART from August 2003 to
March 2006 (31 months). Patients in the no-ART cohort
who later went on receiving ART were excluded from the
no-ART cohort, but included in the ART cohort. Patients
who were under the age of 15 years were excluded from
the study. In the no-ART cohort, the proportions of
patients in the non-AIDS and AIDS states were 0.89 and
0.11 respectively, and in the ART cohort the proportions
were 0.74 and 0.26 in the non-AIDS and AIDS states
respectively (Table 1). The inpatient service use and corre-
sponding costs were derived from 58 HIV patients (33
without ART and 25 with ART) who received inpatient
care at Arba Minch Hospital during 2004/5 Ethiopian fis-
cal year.
Clinical data
The primary clinical outcome of interest was LYG with
and without ART. We collected the following data from
the patients' records: demographic characteristics, date of
starting treatment, clinical stage upon enrolment, pres-
ence of opportunistic infections upon enrolment, investi-
gation performed, drugs used, frequency of outpatient
visit to the HIV clinic, date of progression to another clin-
ical stage, and time of discontinuing care at the HIV clinic
(due to death, lost to follow up or starting ART). The HIV
clinic at AMH maintain a database of the HIV patients
under its care. The community health workers at the clinic
verify and confirm all deathes thar occur outside the hos-
pital through regular home visits and followup. Patients
who were not reported to have died or transferred but
failed to show up within 90 days after their next scheduled
visit were considered as lost to follow-up. Patients were
censored on the date of their transfer, status of lost to fol-
low-up, starting ART or the last date of observation which-
ever came first.
We estimated the disease progression probabilities for
each reiteration interval of the 3-month period (cycle)
using the Kaplan Meier method. For each cycle we calcu-
lated the hazard rates and converted them to the corre-
sponding transition probabilities and their 95%
confidence intervals. Accordingly, for the no-ART cohort,
we arrived at five and four sets of transition probabilities
during observation periods of 1.25 and 1 year for the non-
AIDS and AIDS states, respectively. In the ART cohort, we
estimated eleven sets of transition probabilities for both
the non-AIDS and AIDS states over the observation
period. Tables 2 and 3 report the three month transition
probabilities observed during the follow up period. We
used the average of these probabilities to construct matri-
ces of constant transition probabilities (Table 4), which
we applied to all cycles in the respective no-ART and ART
scenarios in our model.
The Markov states and pattern of HIV disease progressionFigure 1
The Markov states and pattern of HIV disease pro-
gression.
WHO Stage 1, II & 
III 
(non-AIDS) 
WHO Stage IV 
(AIDS) 
Death 
(Absorbing state) 
Table 1: Profile of study subjects
Variables Category no-ART ART
n(%) n(%)
Gender
Female 98(48.3) 88(42.1)
Male 105(51.7) 121(57.9)
Age group
<20 7(3.4) 3(1.4)
20–29 64(31.5) 56(26.8)
30–39 92(45.3) 90(43.1)
40–49 30(14.8) 46(22.0)
>49 10(4.9) 14(6.7)
WHO Clinical Stages
I 22(10.8)
II 30(14.8) 15(7.2)
III 129(63.6) 139(66.5)
IV 22(10.8) 55(26.3)
AIDS status
non AIDS 181(89.2) 154(73.7)
AIDS 22(10.8) 55(26.3)
Total 203(100) 209(100)Page 3 of 11
(page number not for citation purposes)
Cost Effectiveness and Resource Allocation 2009, 7:13 http://www.resource-allocation.com/content/7/1/13Cost data
The costing in our study was done from the health care
provider's perspective and included both outpatient and
inpatient hospital costs. Costs were estimated for both
direct capital and recurrent inputs for the final HIV-related
services, and their shares from the overhead cost centres of
the hospital were also included. The Ethiopian fiscal year
starting 8 July 2004 and ending 7 July 2005 was used as
the base year, and cost data were collected retrospectively.
We retrieved personnel cost and unit costs of each of the
non-medical supplies recurrent inputs from the financial
records of the accounts section of AMH. For capital inputs,
we took the 2005/6 replacement price from the market.
We obtained the 2004/5 price of drugs and medical sup-
plies from the Pharmaceuticals and Medical Supplies
Import and Wholesale Share Company (PHARMID) and
the SNNPR Health Bureau. We used 2005/6 prices if
2004/5 prices were not available. We allocated hospital
overhead costs to the HIV-related services using a step-
ping-down approach [15]. We used the volume of service
during the base year (2004/5) for calculating unit costs of
services, and translated the 2005/6 costs to the base year
2004/5. Average annual outpatient and inpatient costs
and the respective 95% confidence intervals were esti-
mated from the annual cost of the HIV/AIDS health care
service at the hospital. The details of the costing are dis-
cussed elsewhere [13]. All costs were converted to the US
dollar using the average exchange rate in 2004/5 (US$1=
ETB 8.6649) [20].
Then we calculated the three month (i.e. Markov cycle)
average cost (Table 5) for each of the Markov 'alive' states
(i.e. non-AIDS and AIDS) for both the no-ART and ART
scenarios from the respective annual average costs.
Base case cost-effectiveness analysis
At base case analysis, we populated the model with the
initial distribution patients in the no-ART and ART scenar-
ios as observed from the Arba Minch cohort (Table 1), the
Table 2: Three-month transition probabilities (95% CI) to a dead state from the non-AIDS and AIDS states among HIV patients at 
Arba Minch Hospital.
Time interval (in months) no-ART ART
non-AIDS AIDS non-AIDS AIDS
0–3 0.123(0.084–0.177) 0.270(0.143–0.436) 0.099(0.063–0.151) 0.319(0.237–0.409)
3 to 6 0.123(0.099–0.146) 0.178(0.116–0.196) 0.040(0.032–0.046) 0.021(0.018–0.022)
6 to 9 0.076(0.060–0.091) 0.093(0.074–0.108) 0.032(0.026–0.037) 0.046(0.040–0.048)
9 to 12 0.123(0.093–0.149) 0 0.018(0.015–0.022) 0
12 to 15 0 0 0
15 to 18 0.013(0.010–0.017) 0
18 to 21 0 0
21 to 24 0 0
24 to 27 0 0
27 to 30 0 0
30 to 33 0 00
Average of
All quarters
0.090(0.068–0.115) 0.141(0.085–0.194) 0.019(0.013–0.027) 0.040(0.029–0.053)
Table 3: Three-month probabilities (95%CI) of progression from non-AIDS to AIDS state among HIV patients at Arba Minch Hospital.
Time interval in month no-ART ART
0–3 0 0
3 to 6 0.073(0.034–0.150) 0.015(0.004–0.058)
6 to 9 0.043(0.025–0.068) 0.00856(0.004–0.013)
9 to 12 0 0
12 to 15 0.077(0.024–0.182) 0
15 to 18 0
18 to 21 0
21 to 24 0
24 to 27 0
27 to 30 0
30 to 33 0
Average of
all quarters
0.039(0.017–0.083) 0.002(0.001–0.007)Page 4 of 11
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and the three month average costs (Table 5). we assumed
that ART would have a continuous treatment effect and
the survival divergence observed [18] during the first few
cycles would continue throughout the remaining cycles.
The survival pattern between the no-ART and ART cohorts
at AMH showed that, after the first few months of follow
up, the proportion surviving in the ART group became
higher than that of the no-ART group and remained
higher throughout the observation period. Thus, assum-
ing the same survival pattern would also continue after
the follow up, we applied the average of the transition
probabilities observed during the follow-up period to all
cycles in our model. The model is then run for 80 cycles
(20 years) for a hypothetical cohort of patients to estimate
the life expectancies and life time costs.
We present the results in terms of incremental costs, incre-
mental LYG and incremental cost per LYG [15], first
undiscounted and then at a 3 % discount rate. We used
the criteria outlined in the World Health Report 2002 [21]
to assess whether ART is a cost effective intervention in the
Ethiopian setting. The report indicates those interventions
with an incremental cost effectiveness ratio (ICER) within
the value three times the per capita GDP as cost effective;
and those interventions with ICERs less than the per cap-
ita GDP as highly cost effective.
Handling of uncertainties
We used probabilistic sensitivity analysis (PSA) to assess
the overall impact on the results from simultaneous
uncertainties around the input parameters, and present
the result in the form of a cost-effectiveness acceptability
curve (CEAC) [15]. The CEAC illustrates the probability
Table 4: Three month average transition probabilities matrices (no-ART and ART)
no-ART ART
Transition to Transition to
Transition from non-AIDS state AIDS state Death Transition from non-AIDS state AIDS state Death
non-AIDS state 0.87 0.04 0.09 non-AIDS state 0.978 0.002 0.02
AIDS state 0 0.86 0.14 AIDS state 0 0.96 0.04
Death 0 0 1 Death 0 0 1
Table 5: Average three-month (Markov cycle) cost (95% CI) of HIV-related services in US$ * at Arba Minch Hospital by ART and AIDS 
status.
Categories no-ART ART
non-AIDS AIDS non-AIDS AIDS
Outpatient services
HIV clinic consultation 3.37(3.09–3.65) 4.41(2.91–5.85) 8.48(8.19–8.77) 8.43(7.86–9.00)
Laboratory 2.54(2.28–2.79) 3.20(1.87–4.54) 3.37(3.17–3.58) 3.59(3.12–4.06)
Imaging 0.72(0.54–0.90) 1.81(0.70–2.93) 0.11(0.05–0.16) 0.08(0.01–0.17)
Anti retroviral drugs 0.00 0.00 45.98(41.40–50.57) 45.67(35.22–56.12)
Non-Anti-retroviral drugs 2.50(1.89–3.11) 5.60–(1.94–9.24) 0.97(0.76–1.17) 0.88(0.64–1.12)
Total three months cost of
Outpatient services
9.12(8.20–10.04) 15.02(8.88–21.16) 58.91(54.11–63.70) 58.65(48.12–69.19)
Inpatient services:
Laboratory 0.81(0.52–1.09) 0.86(0.63–1.08) 0.83(0.52–1.13) 0.60(0.09–1.10)
Imaging 0.43(-0.01–0.88) 0.68(0.36–0.99) 0.06(-0.7–0.18) 0.19(-0.29–0.67)
Non-Anti-retroviral drugs 2.81(1.93–3.68) 2.85(1.89–3.80) 1.41(0.93–1.90) 1.24(0.23–2.25)
General Care & treatment 8.31(4.27–12.35) 14.43(10.21–18.65) 3.09(2.40–3.79) 6.27(3.89–8.64)
Meal 2.74(1.41–4.07) 4.75(3.36–6.14) 1.02(0.79–1.25) 2.06(1.28–2.85)
Total three months cost of
in-patient care
15.10(8.81–21.38) 23.55(17.81–29.29) 6.41(5.23–7.60) 10.35(6.94–13.77)
* US$1 = 8.6649 Ethiopian birrPage 5 of 11
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of the health care provider to pay for LYG, which is likely
to depend on the availability of resources for health care
in different settings.
To deal with uncertainties related to the model structure
and process, we performed scenario analysis under the
following conditions: (a) if the initial distribution of
patients in the non-AIDS and AIDS Markov states is
changed and all patients start from the non-AIDS Markov
state; (b) if the time horizon of the model evaluation is
extended and the model analysis continue until all the
patients in the ART cohort die; (c) if different amounts of
one time additional costs are included for patients dying
under the ART scenario; and (d) if effect of ART is limited
to cycles that correspond to the observation period and
has no effect thereafter (i.e. Treatment effect only during
the first eleven cycles).
Statistical tools and ethical considerations
We used a CostIt version 4.4 spreadsheet [22] to catego-
rize and summarize the cost data, SPSS version 14.1 and
Stata version 9.2 for the statistical analysis of patient level
data and TreeAge software (Pro 2005 suite version 1.4) for
the cost-effectiveness analysis. Ethical clearance and per-
mission to access hospital records were obtained from the
Southern Nation Nationalities and Peoples Region Health
Bureau. Patients also have given individual written con-
sent before enrolment into the study [18].
Results
Profile of study subjects
No-ART cohort
Two hundred and nine adult HIV patients visited the HIV
clinic at Arba Minch Hospital from January 01, 2003 to
April 08, 2004 (15.2 months). Five of these patients had
incomplete records and one patient died on the day of the
first visit. These patients were therefore excluded from the
study. The remaining 203 (98 women and 105 men) com-
prised the no-ART cohort. Among these, 181 patients
(89.2%) were non-AIDS (WHO clinical stages I, II and III)
and 22 patients (10.8%) had AIDS (WHO clinical stage
IV) (Table 1). During the follow-up period 53 patients
(26.1%) died; 1 patient (0.5%) was transferred; 31
patients (15.3%) were lost to follow-up; 45 patients
(22.2%) were switched to ART; and 73 patients (36%)
were under care until the last date of the follow up. The
median follow-up period was 14.6 weeks. The mean age
of the cohort was 32.6 years and the average monthly
income was US$23.43.
ART cohort
Two hundred and ten adult HIV ART patients visited the
HIV clinic from August 01, 2003 to March 09, 2006 (31.2
months). One patient had incomplete records, and was
excluded from the study. Thus, 209 patients (88 women
and 121 men) comprised the ART cohort. Out of these,
154 patients (73.7%) were in the non-AIDS stages and 55
patients (26.3%) had AIDS (Table 1). During the follow-
up period 53 patients (25.4%) died; 13 patients (6.2%)
were transferred to other ART sites that were close to
where the patients lived; 21 patients (10%) were lost to
follow-up; and 122 patients (58.4%) were under care
until the last date of the follow up. The median follow up
period was 49.14 weeks. The mean age was 34.4 years and
the average monthly income was US$30.12.
Base case analysis
Expected survival and lifetime cost
For the no-ART scenario, the undiscounted expected sur-
vival in the non-AIDS and AIDS states were 1.6 and 0.7
years, respectively, and the total life expectancy was 2.3
years. The expected total lifetime cost of care to HIV
patients without ART was US$265 and the average PPY
cost is US$114 (Table 6).
For ART, at base case, the total undiscounted life expect-
ancy was 9.4 years. The respective survival times before
progressing to the next worst state in the non-AIDS and
AIDS states were 7.3 and 2.1 years, respectively. The
expected lifetime cost of treating patients with ART was
US$2,479 with an average cost of US$265 PPY.
Incremental costs and cost-effectiveness
The cost-effectiveness analysis showed that ART is both a
more costly and more effective scenario compared with
the no-ART scenario. ART prolonged the life of patients by
an average of 7.1 years with an additional lifetime cost of
US$ 2,215, resulting in an average undiscounted incre-
mental cost-effectiveness ratio (ICER) of US$314 per LYG
(Table 6). The ICER represents the additional cost needed
over the cost of no-ART to extend life expectancy by one
more year. When both costs and effects are discounted at
3%, the average extra LYG decreases to 5.5; and the aver-
age incremental cost per additional LYG (i.e. ICER)
increases to US$325. (Table 6)
Uncertainties
Parameter uncertainty
Figure 2 summarizes the probabilistic sensitivity analysis
(PSA) results. The cost-effectiveness acceptability curve
suggests the probability of ART being cost-effective for dif-
ferent levels of willingness to pay for a LYG. Accordingly,
the probability that ART will be cost effective is about 85%
given the level of willingness to pay as approximated by
the value 3 times the base year per capita GDP of US$169
[23] in Ethiopia (i.e. US$507).
Scenario analysis and comparison with base case cost-effectiveness
Table 7 summarizes the results of the scenario analysis. At
base case, patients were distributed into the non-AIDS
and AIDS Markov states as observed from the Arba MinchPage 6 of 11
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the patients in each cohort were initially in the non-AIDS
state, the Markov cohort analysis resulted in an average of
8 LYG with an average incremental cost of US$307 per
LYG (Table 7-a) compared to the averages 7.1 extra LYG
and US$314 incremental cost in the base case result.
Regarding the time horizon, the base case analysis was
based on evaluation of the model for 80 cycles (i.e. 20
years); and a significant proportion of the ART hypotheti-
cal cohort was alive when the model stopped running. In
the alternative scenario, we removed the 20-year assump-
tion and ran the model until all the patients in the cohort
would die. This resulted in increased life expectancy,
increased lifetime cost and a 3.5% reduction in the aver-
age incremental cost per LYG or the ICER (Table 7-b).
The pattern of service use and corresponding costs, in our
study, would be higher in the no-ART scenario if the costs
of ARV were removed from the ART scenario. In the base
case analysis we assumed that this difference might
implicitly reflect that the cost of dying was captured in
both the no-ART and ART wings. To assess the sensitivity
of this assumption and its potential effect on the base case
ICER, we analyzed the model under three different scenar-
ios of additional cost of dying for patients dying under the
ART scenario. We used additional dying costs of $70,
$117 and $233, which were respectively the three, five
and ten times the three month average cost for AIDS
patients under ART, which was US$ 23.3 excluding the
cost of ARV drugs. This resulted in increased per LYG aver-
age costs (i.e. ICERs) that range from US$322 to US$341
with a maximum of 9% increase from the base case ICER
(Table 7-c).
While the alternative scenarios described above (Table
7a–c) had only relatively small effects on the cost effec-
tiveness of ART, the impact of a pessimistic assumption
about future treatment effect was more substantial. At
base case, we assumed a continuous treatment effect of
ART. In contrast to this, in an alternative scenario, we
assumed that ART would have no effect after the actual
follow-up period. Thus, we applied the average transition
probabilities of the no-ART scenario to the ART scenario
after the eleventh Markov cycle (i.e. for Markov cycles
beyond the follow-up period). Under this scenario, while
the base case incremental cost per LYG (i.e. the ICER)
increases by 41%, the additional LYG and corresponding
additional lifetime cost decrease by 72% and 60% respec-
tively (Table 7-d). The probability that ART would be cost-
effective also decreases to 58%.
Discussion
Principal findings
At base case, ART resulted in 7.1 extra LYG with lifetime
incremental cost of US$2,215 and undiscounted incre-
mental cost per LYG of US$314. However, the extra LYG
increases to 8 years and the incremental cost PPY reduces
to US$307 if the ART is started while the patients are in
the non-AIDS state (i.e. WHO clinical stages I–III) and
Table 6: Base case cost-effectiveness (95% CI) of ART compared with no-ART
Strategy Life time
Cost $
Life time
incremental
cost$
Life years
gain
Incremental
life years gain
Cost
effectiveness ($)
Incremental
Cost
Effectiveness
ratio (ICER $)
% change
from base
case ICER
Undiscounted
no-ART 265(86–1148) 2.3(1.95–2.73) 114(38–504)
ART 2479
(1214–4828)
2215
(771–4635)
9.4(8.67–10.05) 7.1(6.24–7.83) 265(130–513) 314(111–654)
Discounted at 
3%
no-ART 247(80–1008) 2.2(1.83–2.56) 114(37–471)
ART 2028
(1000–3868)
1780
(577–3710)
7.7(7.15–8.18) 5.5(4.85–6.13) 265(131–508) 325(106–680) 3.5
Cost-effectiveness acceptability curve for ARTFigur  2
Cost-effectiveness acceptability curve for ART.
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IV). The result is sensitive to assumptions about the
extrapolation of the treatment effects of ART, but stable to
discounting, extending the time span of the model evalu-
ation and the inclusion of separate cost of dying.
There are no benchmark values for cost-effectiveness in
the Ethiopian context. However ART appears cost effective
when compared with the threshold suggested in the
World Health Report 2002 [21]. The report suggests that
interventions costing less than per capita GDP per LYG are
highly cost effective, and interventions costing less than
three times the per capita GDP are cost effective Though
the incremental cost per LYG under the assumption of
reducing treatment effect of ART was considerably higher
than that of the base case, all the incremental costs per
LYG are less than three times the per capita GDP
(US$169) at the base year [23], i.e. US$507 (Tables 6
and 7).
Discussion of main findings
The incremental LYG through ART are fewer in our study
than has been reported from South Africa by Cleary et al
[7], who reported 10 undiscounted and 6.8 discounted
incremental life years through ART. Though there could
be several reasons for these differences, one reason for
observing fewer extra LYG in our study could be the time
horizon used in our model. We set the time horizon of our
study to 20 years (80 cycles). The alternative scenario of
running the model until all the patients in each cohort die
would yield 9.1 extra undiscounted LYG with ART, which
is comparable to the South African study.
While the base case LYG in our study was smaller than
previously modelled, the incremental cost-effectiveness
appears more favourable than previously observed
[4,7,9]. When the incremental costs are adjusted to a com-
mon year (i.e. 2005 US$), the estimate from Cote d'Iviore
ranges from US$574 to US$874 and that of South Africa
Table 7: Cost-effectiveness (95% CI) of ART compared to no-ART under different scenarios
Strategy Life time
Cost $
Life time
incremental
cost
Life years
gain
Incremental life
years gain
Cost
effectiveness ($)
Incremental Cost
Effectiveness ratio
(ICER $)
% change from
base case ICER
a)
no-ART 264(82–1046) 2.4(1.99–2.82) 110(36–433)
ART 2713
(1038–5883)
2448(653–5665) 10.4
(9.45–11.23)
8(6.96–8.91) 262(101–564) 307(83–708) -2.2
b)
no-ART 265(85–1148) 2.3(1.95–2.73) 114(38–504)
ART 3022
(1486–6054)
2757
(1080–5885)
11.4
(10.46–12.41)
9.1(8.03–10.18) 264(129–525) 303(121–634) -3.5
c)
no-ART 265(85–1148) 2.3(1.95–2.73) 114(38–504)
ART* 2537
(1281–4859)
2273(851–4647) 9.4
(8.67–10.05)
7.1(6.24–7.83) 271(137–519) 322(120–662) 2.6
ART** 2576
(1313–4937)
2311(844–4740) 9.4
(8.67–10.05)
7.1(6.24–7.83) 275(141–525_ 328(123–668) 4.5
ART*** 2672
(1413–5069)
2407
(1020–4841)
9.4
(8.67–10.05)
7.1(6.24–7.83) 285(151–539) 341(145–684) 8.6
d)
no-ART 265(85–1148) 2.3(1.95–2.73) 114(38–504)
ART 1150
(621–2099)
886(-100–1924) 4.3(3.99–4.67) 2.0(1.49–2.53) 266(145–482) 441(-49–1009) 40.5
a) if all patients initially start from the non-AIDS state
b) if the model runs until all the patents in the ART cohort die
c) if different amounts of one time additional costs are included for patients dying under the ART scenario
d) if effect of ART is limited to cycles that correspond to the observation period and has no effect thereafter.
(i.e. Treatment effect only for the first 11 cycles)
* if additional cost for dying patients = $70
** if additional cost for dying patients = $117
*** if additional cost for dying patients = $233Page 8 of 11
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however, be careful in making direct comparison of the
cost-effectiveness values of different settings due to varied
assumptions and contexts [24]. Nevertheless, the lower
prices of labour and non-traded inputs in Ethiopia might
have lowered the cost estimates.
Study limitations
We categorized the course of HIV into the Markov states
based on the WHO clinical staging system [12], which is
commonly applied in settings where immunological and
virological measures are not available. However, as the
Markov non-AIDS state included 3 distinct stages (i.e.
WHO clinical stages I–III) with assumable varied risk of
progression, ideally it might have been better to have
applied a Markov model with the corresponding number
of health states. This was, however, not feasible in our case
because of limited data. In addition, in our model, the ini-
tial proportion of patients in the AIDS state under ART
was higher than those under no-ART. This might have
introduced bias as those patients in the AIDS state are
likely to have higher mortality. The higher proportion of
AIDS patients under ART was due to the fact that when the
ART program was initiated at AMH, there were already a
considerable number of AIDS cases and priority was given
to those patients thereby increasing the number of AIDS
cases under ART. The model corresponds well with the
nature of the empirical evidence.
As mentioned, we also assumed a continuous treatment
effect of ART and applied the average transitional proba-
bilities observed during the follow-up period to all the
Markov cycles. The sensitivity analysis indicated that mak-
ing different assumptions about this has relatively large
implications for cost-effectiveness estimates. The reason
for assuming a continuous treatment effect of ART was
that the survival pattern along the no-ART and ART
cohorts at Arba Minch Hospital showed that the short-
term survival curves of the cohorts diverged within the
first 6-month observation and continued to diverge even
more as the mortality under ART tended to stabilize [18].
Nevertheless, there are indications that treatment side
effects and drug resistance are possibilities in the long
course of ART [25-27]. Such undesirable outcomes have
the potential to dilute the treatment effect in the long run
and may eventually result in an increased disease progres-
sion even under treatment, resulting in increased cost.
From this perspective, our assumption of continuous
treatment effect might have underestimated the disease
progression under the ART scenario in the long run and
overestimated the corresponding survival. The alternative
scenario where the effectiveness of ART was assumed to
decrease after the follow-up period resulted in reduced
LYG and higher incremental cost per LYG (Table 7-d).
However, the assumption that ART will not have an effect
after the observation period is an extreme scenario and
might be unlikely. Though the mortality of HIV patients
treated with ART is still higher than that of the general
population in the sub-Saharan Africa, there is an indica-
tion that it is becoming comparable to that of the general
population as the treatment continues [28].
Another potential limitation is that we measured the
health outcome in terms of LYG. This is a straight forward
choice of method, but imposes some restrictions on the
generalizability of the results. Our method provides useful
information on life expectancies, but does not capture the
morbidity dimension of the health improvement and,
therefore, does not reveal the full benefit of ART [29,30].
As HIV/AIDS is a life long problem, incorporating the
health improvements of ART using Quality Adjusted Life
Years (QALY) would have enriched the results. However,
no quality of life weights for HIV patients in Ethiopia are
available. In the choice between using disability weights
(DALYs) with questionable validity for countries such as
Ethiopia or the less commensurable LYG [29], we chose
the latter approach. The choice of LYG as a measure of
health benefits may have biased our estimates conserva-
tively.
The identification, measurement and valuation of the
costs followed an ingredient approach. Most of the costs
associated with the HIV-related services and overhead
activities were, therefore, included in the cost estimation.
Nevertheless, there are few uncertainties and shortcom-
ings in our costing approach. First, we applied average
rather than marginal unit costs in the cost analysis, which
is a problem if the unit costs are much affected by the vol-
ume of service delivered during a specified period [15].
Service categories that operate below their full capacity,
for example, are likely to have higher average rather than
marginal costs, while the marginal costs of services oper-
ating above the limit of their capacity are likely to be
higher than the average costs. Second, due to the difficulty
in retrieving retrospective inpatient service use data for
HIV patients at Arba Minch hospital, we based the esti-
mate of inpatient costs on a single year service use data
which may not fully reflect the pattern of use of service
over a number of years.
The assessment of cost effectiveness relative to GDP
thresholds assumes both societal costs and gains. Taking
only the health care provider's perspective may not reflect
the full societal costs. Therefore, the omission of logistic
costs and patient-incurred costs, such as transport costs
and lost productivity due to care seeking, might have thePage 9 of 11
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it actually is. On the other side we excluded patient level
indirect costs including productivity changes. ART often
improves patients' health to a level that enables them to
resume their usual subsistence activities. These effects, if
included, might have pulled the cost effectiveness in a
more favourable direction. We believe our costing per-
spective is conservative.
Conclusion
The estimated annual average cost has direct implications
for program management. In rural district hospital set-
tings, Ethiopia would need to spend about US$265 per
patient per year to deliver ART. This may help in planning,
budgeting and financing for expanding ART in Ethiopia.
Nevertheless, though there may be no major differences in
the epidemiology of HIV and prices of major inputs across
the country, the cost drivers are likely to be different across
levels of hospitals. Therefore, our cost findings may not
reflect the pattern in the relatively cosmopolitan centres
where major tertiary hospitals operate. However, as Arba
Minch Hospital is a typical district hospital in Ethiopia,
our findings may be extended to other district hospital set-
tings in the country.
Our study is the first economic evaluation of ART in an
Ethiopian context and may have implications for scaling
up AIDS treatment in the country. According to the WHO
guideline [21], ART in Ethiopia appears cost effective,
though may not be regarded as highly cost effective. The
incremental cost per additional LYG is below three times
the per capita GDP, but it is above the per capita GDP,
implying a need for more economically efficient ways of
delivering ART. This may involve investigating: (i)
whether providing ART through integrated service is pref-
erable to specialized clinics, and (ii) the cost-effectiveness
of delivering ART through health centres compared to
hospitals.
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